Skip to main content
Caplight Logo









Glucox Biotech AB

Glucox Biotech AB

Private
SwedenHealthcare & Life Scienceshttps://www.glucoxbiotech.com/

Last Round

Grant

Aug 15, 2022

Total Funding Raised

$560,000

Company Overview

Glucox Biotech AB is a biotechnology company that develops selective NOX4 inhibitors for the treatment of metabolic diseases, including type 2 diabetes, diabetic retinopathy, ischemic stroke, and acute kidney injury.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

small-molecule therapeuticsNOX4 inhibitorsdrug discoverybiotechNADPH oxidaseNOXpreclinical drug developmentmetabolic disease treatmentdiabetic retinopathyreactive oxygen speciesROSpharmaceutical R&Ddrug pipelinebiotech startuptherapeutic licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Glucox Biotech AB Comparables

Compare Glucox Biotech AB with similar companies based on industry and business-model similarity.

Glucox Biotech AB comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
D-Sight
85%
AptaBio Therapeutics Inc
80%
FibroNox
80%

Glucox Biotech AB Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 15, 2022
Early FundingJun 7, 2018
GrantOct 7, 2013
GrantDec 15, 2012

Glucox Biotech AB Investors

Notable investors and investment history

Glucox Biotech AB investors
InvestorRounds
Eurostars SME programmeGrant
European Regional Development FundGrant
VinnovaGrant
SLU Holding ABGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 15, 2022

    Received funding from the Eurostars SME programme.

  • Jun 7, 2018

    Led by Björn Sundeby with participation from Dan Hasson and Tore Bengtsson.

Glucox Biotech AB Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Glucox Biotech AB Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Glucox Biotech AB's valuation, stock price, and market status.

Firmographic Details

HeadquartersSweden
Employee Range1
Year Founded2003
Last FundingAug 15, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?